Insights

Innovative Therapeutics Merus specializes in developing multispecific antibody therapies, including Biclonics and Trispecifics, which present opportunities for collaborations or licensing deals with partners seeking cutting-edge oncology treatments.

Strategic Collaborations Recent partnerships with Foundation Medicine and Partner Therapeutics to develop targeted therapies and RNA diagnostic platforms highlight potential avenues for joint ventures or co-development initiatives in precision oncology diagnostics and therapeutics.

Expanding Market Presence Participation in prominent healthcare conferences like BofA Securities 2025 indicates Merus’s active engagement in industry networking, opening doors for sales outreach to other biotech firms and research institutions interested in novel cancer therapeutics.

Clinical Development Pipeline With multiple candidate drugs in clinical trials and a focus on bispecific and trispecific antibodies, there is a significant opportunity to support or supply ancillary services, testing platforms, or complementary products to accelerate clinical progress.

Focus on Precision Medicine The company's emphasis on targeted therapies for specific cancer subtypes such as NRG1+ tumors creates potential for sales involving biomarker detection tools, companion diagnostics, and patient stratification solutions.

Similar companies to Merus N.V.

Merus N.V. Tech Stack

Merus N.V. uses 8 technology products and services including Google Hosted Libraries, WordPress, Webpack, and more. Explore Merus N.V.'s tech stack below.

  • Google Hosted Libraries
    Content Delivery Network
  • WordPress
    Content Management System
  • Webpack
    Development
  • Twitter Emoji (Twemoji)
    Font Scripts
  • Swiper
    Javascript Libraries
  • YouTube
    Video Players
  • Acquia Cloud Site Factory
    Web Hosting
  • Drupal Multisite
    Web Hosting

Media & News

Merus N.V.'s Email Address Formats

Merus N.V. uses at least 1 format(s):
Merus N.V. Email FormatsExamplePercentage
F.Last@merus.nlJ.Doe@merus.nl
73%
First.Last@merus.nlJohn.Doe@merus.nl
14%
First_Last@merus.nlJohn_Doe@merus.nl
13%

Frequently Asked Questions

Where is Merus N.V.'s headquarters located?

Minus sign iconPlus sign icon
Merus N.V.'s main headquarters is located at Yalelaan 62, Utrecht, Utrecht 3584 CM, NL. The company has employees across 2 continents, including EuropeNorth America.

What is Merus N.V.'s phone number?

Minus sign iconPlus sign icon
You can contact Merus N.V.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Merus N.V.'s stock symbol?

Minus sign iconPlus sign icon
Merus N.V. is a publicly traded company; the company's stock symbol is MRUS.

What is Merus N.V.'s official website and social media links?

Minus sign iconPlus sign icon
Merus N.V.'s official website is merus.nl and has social profiles on LinkedInCrunchbase.

How much revenue does Merus N.V. generate?

Minus sign iconPlus sign icon
As of September 2025, Merus N.V.'s annual revenue reached $75M.

What is Merus N.V.'s SIC code NAICS code?

Minus sign iconPlus sign icon
Merus N.V.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Merus N.V. have currently?

Minus sign iconPlus sign icon
As of September 2025, Merus N.V. has approximately 300 employees across 2 continents, including EuropeNorth America. Key team members include Chief Executive Officer: M. C.Chief People Officer: A. B.Chief Medical Officer: F. Z.. Explore Merus N.V.'s employee directory with LeadIQ.

What industry does Merus N.V. belong to?

Minus sign iconPlus sign icon
Merus N.V. operates in the Biotechnology Research industry.

What technology does Merus N.V. use?

Minus sign iconPlus sign icon
Merus N.V.'s tech stack includes Google Hosted LibrariesWordPressWebpackTwitter Emoji (Twemoji)SwiperYouTubeAcquia Cloud Site FactoryDrupal Multisite.

What is Merus N.V.'s email format?

Minus sign iconPlus sign icon
Merus N.V.'s email format typically follows the pattern of . Find more Merus N.V. email formats with LeadIQ.

How much funding has Merus N.V. raised to date?

Minus sign iconPlus sign icon
As of September 2025, Merus N.V. has raised $300M in funding. The last funding round occurred on Jun 03, 2025 for $300M.
Merus N.V.

Merus N.V.

Biotechnology ResearchNetherlands201-500 Employees

Merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.

Working at Merus offers opportunity to grow and develop a career that offers both individual and company success. You have the chance to make an impact within the oncology field by being part of the development of bispecific antibody therapies (Biclonics®) to help fight cancer. Merus’ Head Quarters are located in The Netherlands, with offices in the US and collaborators around the world. As of 2016 we are listed on NASDAQ and over a period of 10 years we have several candidate drugs in clinical trials. For more information, please visit www.merus.nl
Read our Community Guidelines: https://merus.nl/community-guidelines/

Section iconCompany Overview

Headquarters
Yalelaan 62, Utrecht, Utrecht 3584 CM, NL
Phone number
Website
merus.nl
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
MRUS
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
201-500

Section iconFunding & Financials

  • $300M

    Merus N.V. has raised a total of $300M of funding over 12 rounds. Their latest funding round was raised on Jun 03, 2025 in the amount of $300M.

  • $50M$100M

    Merus N.V.'s revenue is in the range of $50M$100M

Section iconFunding & Financials

  • $300M

    Merus N.V. has raised a total of $300M of funding over 12 rounds. Their latest funding round was raised on Jun 03, 2025 in the amount of $300M.

  • $50M$100M

    Merus N.V.'s revenue is in the range of $50M$100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.